Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
\- Patients under alirocumab 300mg treatment.
Exclusion Criteria:
* Age \< 18 years o \> 80 years;
* Patients who refuse to participate and to sign informed consent.
Primary outcome measure(s)
Description of adherence of treatment with alirocumab 300mg in a real-life Italian population. — 6-12-24-36 months Adherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Description of persistence of treatment with alirocumab 300mg in a real-life Italian population. — 6-12-24-36 months Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
Description of efficacy of treatment with alirocumab 300mg in a real-life Italian population. — 6-12-24-36 months Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value).
Trial sites (1)
Facility
City
Region
Status
Federico II University of Naples, Department of Advanced Biomedical Sciences
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.